Sarah Meibusch
Partner
| Healthcare
| Location: Brisbane, AU
Sarah is a Partner at OneVentures, focused on sourcing and supporting life sciences companies developing transformative technologies with global potential.
She currently serves as Chair of Axial Therapeutics, a Board Member for Kira Biotech and an Alternate Board Member and Observer for Vaxxas, Clinical Genomics and Prota Therapeutics.
Sarah brings over 20 years of enterprise-level leadership experience across the life sciences ecosystem, from agriculture to healthcare. Her career spans start-ups, private and public companies (ASX- and NASDAQ-listed), multinational pharma, and university research organisations. She has a strong track record in deal-making, from early-stage investments and university collaborations to major pharma transactions worth hundreds of millions of dollars.
Prior to joining OneVentures, Sarah held roles in business development and commercial strategy in Australia and the United States, combining deep scientific expertise with commercial acumen to drive innovation to market.
Sarah holds a Bachelor of Agricultural Science with First Class Honours from the University of Queensland and a Master’s in Genomics from Cornell University. She has post-graduate training in negotiation from Harvard and is a Graduate of the Australian Institute of Company Directors (GAICD). She is also a member of the QIMR Berghofer Medical Research Institute Commercial Advisory Board and the AusBiotech Investment Advisory Group.
| BAgrSc(Hons), M.P.S, GAICD
